Healthcare Sector Announced Financial Results and Recognition - Research Report on Alnylam Pharmaceuticals, Opko, Enzymotec, Cambrex, and XOMA
NEW YORK, November 15, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), Opko Health, Inc. (NYSE: OPK), Enzymotec Ltd. (NASDAQ: ENZY), Cambrex Corporation (NYSE: CBM), and XOMA Corporation (NASDAQ: XOMA). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Alnylam Pharmaceuticals, Inc. Research Report
On November 6, 2013,Alnylam Pharmaceuticals, Inc. (Alnylam) reported its financial results for Q3 2013. The Company's revenue from research collaborators decreased 46.4% YoY to $9million during the quarter. Net loss was $29.7 million or $0.48 per diluted share in Q3 2013, compared to net loss of $19.5 million or $0.38 per diluted sharein Q3 2012. Commenting on the results,John Maraganore, Ph.D.,CEO of Alnylam, said, "This was a quarter of remarkable progress at Alnylam. A key highlight was achievement of positive data from our Phase I clinical trial with ALN-TTRsc in development for the treatment of familial amyloidotic cardiomyopathy. In this study, we demonstrated knockdown of serum TTR of up to 94% and showed that ALN-TTRsc was generally safe and well tolerated, thereby confirming human translation of our proprietary GalNAc-siRNA conjugate delivery platform. As such, we believe these data are very important not only for our ALN-TTRsc program, but for the entirety of our 'Alnylam 5x15' pipeline which employs this now clinically validated delivery approach." The Full Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/5b29_ALNY
Opko Health, Inc. Research Report
On November 11, 2013, Opko Health, Inc. (Opko) reported its financial and operational highlights for Q3 2013. The Company's revenue was $20.6 million during the quarter, compared to $11.8 million in Q3 2012. Net loss was $60.0 million in Q3 2013, compared to a net loss of $10.2 million in Q3 2012. Additionally, the Company informed about its initiation of a multi-center study on November 4, 2013, which is expected to generate data to support the launch of the 4Kscore™ test as a laboratory developed test through its Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified laboratory in Nashville, Tennessee. The Full Research Report on Opko Health, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/cd43_OPK
Enzymotec Ltd. Research Report
On November 11, 2013, Enzymotec Ltd. (Enzymotec) reported its financial results for Q3 2013. Net revenue increased 66.3% YoY to $17.8 million during the quarter. Net income was $3.3 million or $0.13per diluted share in Q3 2013, compared to net income of $1.7million or $0.10 per diluted share in Q3 2012. Commenting on the results, President and CEOof Enzymotec, Dr. Ariel Katz said, "We are pleased to report a very strong quarter, highlighted by record sales, cash flow and profitability. Our top line performance was driven by robust performance in both our Nutrition and VAYA Pharma segments, which grew 68.9% and 159.7% year-over-year, respectively." The Full Research Report on Enzymotec Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/f522_ENZY
Cambrex Corporation Research Report
On November 5, 2013, Cambrex Corporation (Cambrex) announced that the Company's name featured in an article, titled "Nice-Sized - A Pharmaceutical Manufacturer Says It Has What It Takes to Serve Clients Both Large And Small" in the magazine, Manufacturing Today's fall 2013 issue. According to the article, the Company's sales reached $277.9 million in 2012 and it anticipates the same to grow in the range of 8%-12% in 2013, strengthening its position in the industry. Simon Edwards, VP of Global Sales and Business Development at Cambrex, said, "It's a mid-sized company with a really good balance. It's almost a unique balance because we have custom manufacturing, generic API and formulated drug product capabilities. We are not a big behemoth and are small enough to be customer focused." The Full Research Report on Cambrex Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/1169_CBM
XOMA Corporation Research Report
On November 7, 2013,XOMA Corporation (XOMA) reported its financial results for Q3 2013. Revenue fell 12.9% YoY to $6.3 million during the quarter. XOMA had a net loss of $29.6 million or $0.34 per diluted share in Q3 2013, compared with a net loss of $26.9 million or $0.39 per diluted share inQ3 2012. Commenting on the results, CEO of XOMA, John Varian said, "By the end of October, we received the initial data from all four pyodermagangrenosum patients enrolled in our pilot study, as well as data from two patients with generalized pustular psoriasis who received gevokizumab under a compassionate use protocol. These two rare indications fall under the neutrophilicdermatoses umbrella, which are a group of conditions that are characterized by skin lesions that have intense epidermal and/or dermal inflammatory infiltrates, yet show no sign of infection. While we have treated only a very small number of patients, the apparent responses are compelling." The Full Research Report on XOMA Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
http://www.analystscorner.com/r/full_research_report/9a56_XOMA
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article